Diabetes: Difference between revisions

60 bytes added ,  23 December 2012
no edit summary
No edit summary
No edit summary
Line 224: Line 224:
*Increased risk of Human gastrointestinal tract|gastrointestinal problems
*Increased risk of Human gastrointestinal tract|gastrointestinal problems
*Contraindicated for people with moderate or severe kidney disease or heart failure because of risk of lactic acidosis
*Contraindicated for people with moderate or severe kidney disease or heart failure because of risk of lactic acidosis
*Increased risk of Vitamin B12 deficiency<cite>63</cite>
*Increased risk of Vitamin B12 deficiency<cite>63</cite><cite>65</cite><cite>66</cite>
*Less convenient dosing
*Less convenient dosing
*Metallic taste<cite>63</cite>
*Metallic taste<cite>63</cite><cite>65</cite><cite>66</cite>
|-
|-
|Alpha-glucosidase inhibitor (acarbose, miglitol)
|Alpha-glucosidase inhibitor (acarbose, miglitol)
467

edits